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Fibrates are drugs used for the treatment of hypertriglyceridemia and for the prevention of atherosclerosis. 
Three drugs in the fibrate class, ciprofibrate, fenofibrate and bezafibrate, were chosen for this study 
because their raw materials are readily available and because scientific publications on these compounds 
is limited. To evaluate their intrinsic stability, the drugs were exposed to a test condition (temperature, 
oxidation, UV light exposure, hydrolysis at different pH values and metal ions in solution) and then were 
subjected to analysis by HPLC. The samples were run on a C18 column, with a flow rate of 1.0 mL min-1 
in a mobile phase consisting of methanol: 0.01 % phosphoric acid v/v (80:20), with variable detection 
wavelengths in the UV spectra. The analysis methodology showed satisfactory performance parameters. 
The three drugs were very unstable, degrading in each of the conditions evaluated. The test conditions 
of acid and basic hydrolysis showed the most significant degradation. The results demonstrated that the 
drugs in this class are unstable. Based on these experimentally determined degradation kinetics, it is 
easy to understand and emphasize the importance of the lack of liquid dosage forms on the market for 
fibrates because of their instability.
Uniterms: Hypertriglyceridemia/fibrates. Fibrates stability/study. Fibrates degradation products/High 
Perfomance Liquid Chromatography (HPLC). Fibrates/Degradation kinetics.
INTRODUCTION
Fibrates  are  drugs  used for  the  t reatment 
of hypertriglyceridemia and for the prevention of 
atherosclerosis, and are represented by the following 
compounds: clorfibrate, ciprofibrate, bezafibrate, 
fenofibrate and geozila. Fibrates decrease triglyceride 
levels and increase HDL-C levels, the latter effect is 
more pronounced in patients with hypertriglyceridemia. 
The effect on LDL-C levels varies. They may reduce 
LDL-C levels in patients with low triglycerides, but 
may paradoxically increase levels for patients with high 
triglyceride levels. Fibrates also significantly reduce the 
levels of highly atherogenic remnant lipoproteins, and 
are more efficient than statins in doing so (Schulz, 2006).
Among the fibrates, three drugs were chosen for 
the execution of this project: ciprofibrate, fenofibrate 
and bezafibrate (Figure 1). The drugs were chosen based 
on the availability of raw materials and evidence of few 
scientific publications regarding the drugs on the subject 
of research.
Some analytical methods have been developed for 
the analysis of ciprofibrate, fenofibrate and bezafibrate by 
HPLC/UV (Nascimento et al., 2011; Salama et al., 2011; 
Jain et al., 2012; Kumbhar et al., 2013; Wei et al., 2008). 
The vast majority of these analytical methodologies used 
reverse phase columns, mainly octadecyl silane, with a 
controlled acidic pH solution for the mobile phase and 
detection in the ultraviolet range.
Few articles have been published on the stability 
of the chosen fibrates (Salama et al., 2011; Jain et al., 
2012; Kumbhar et al., 2013), and none were found that 
identified degradation products, the hypothesized route 
of degradation, or studied the degradation kinetics of 
these drugs. Excipients are chosen for pharmaceutical 
formulations based on the stability data, for the purpose 
of obtaining a more stable formulation. It is noted that 
fenofibrate is an ester and bezafibrate is an amide, which 
makes them very susceptible to hydrolysis reactions.
According to the biopharmaceutics classification 
system (BCS), fibrates are class II drugs with low 
solubility and high permeability (Benet, 2006). Any 
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change in the quality of a class II drug caused by stability 
problems directly influences the bioavailability of the drug 
(Yoshida et al., 2010, 2011).
The HPLC analytical methodology must be 
optimized for the determination of the parent drug as 
well as possible degradation products obtained under 
conditions of intrinsic stability testing. Chromatographic 
performance parameters should be evaluated after 
technical optimization, such as the retention factor (k’), 
number of theoretical plates/column (N), resolution (Rs) 
and tail factor or asymmetry (T) (ANVISA, 2010).
In developing a pharmaceutical formulation, it is 
important to determine the intrinsic stability of the drug 
to predict possible reactions and degradation products 
(Silva et al., 2009). The stability of the substance 
should be evaluated for a number of stressors including 
temperature changes, oxidation, UV light exposure and 
hydrolysis at different pH values. The photostability can be 
evaluated by subjecting the compound to UV irradiation. 
Some degradation pathways can be complex. Not all 
decomposition products formed under the more drastic 
conditions of intrinsic stability are seen in drugs subjected 
to the official conditions of stability studies (USP, 2014; 
Silva et al., 2009; ANVISA, 2005).
In accordance with the regulations, it is important 
to exhaust the possibilities of all drug reactions that 
have not been explored fully (Silva et al., 2009; USP, 
2014; ANVISA, 2005). It is also important to propose 
degradation mechanisms, study the kinetics of the 
reactions, and evaluate the pharmaceutical formulation 
and compare it with the choice of excipients used.
To research the degradation products, drugs are 
subjected to drastic conditions including neutral, acid or 
basic hydrolysis, oxidation with peroxide, exposure to 
UV light, degradation with metal ions (FeSO4) and heat 
(ANVISA, 2005, 2013). The analysis must be performed 
by HPLC and probabilistic mechanisms of possible 
degradation reactions should be proposed.
Kumbhar et al. (2013) reports that fenofibrate 
undergoes rapid degradation through acid and basic 
hydrolysis, and under hydrogen peroxide-mediated 
oxidation. Jain et al. (2012) reports that ciprofibrate is 
unstable to acid hydrolysis, basic hydrolysis and under 
oxidation.
Degradation kinetics are also used to assess the 
stability of drug is where the extent of degradation, t90 (time 
to degrade 10% of the drug), degradation rate, easiness of 
degradation (which is related to the Energy Activation of 
the reaction), and it becomes interesting in comparison of 
stress conditions establishing a proportionality logic and 
for chemical reactions. Thus, intrinsic stability and kinetic 
studies are key components in the discovery of potential 
drug degradation products, even though these products 
may not occur under normal medication storage conditions 
(Yoshida et al., 2010, 2011).
After defining the conditions under which the drugs 
degrade, we conducted a study that included different 
collection times in order to determine the progression of the 
degradation reactions. Then chemical and mathematical 
studies were conducted to determine the activation energy 
(Ea), pre-exponential factor, rate of reaction (k) and finally, 
estimates for the time required to degrade 10% of the drug 
(t90) in a specific condition, usually at 298 K, which is the 
standard storage temperature for pharmaceutical products. 
The t90 is often interpreted as the shelf-life of a drug. This 
is calculated through an extrapolation of the Arrhenius 
equation, and the value determines the drug lifetime at 298 
K (Cides et al., 2006; Yoshida et al., 2010, 2011).
The following equations can be used to describe the 
observed kinetics of degradation in solution:
Arrhenius equation (1):
  (1)
where: k = rate constant, Ea = activation energy, A = pre-
ORDER
ZERO FIRST SECOND
C = -kT + Co 
t90 = (0.1 x Co)/k
log C = -kT / 2.303 
+ log Co 
t90 = 0.105 / k
1/C = kT + 1/Co 
t90 = 1 / (9 x k x Co) 
C = concentration (%); k = rate constant (s- 1); Co = initial 
concentration; t = time (s).
FIGURE 1 - Molecular structure of (a) bezafibrate, (b) ciprofibrate, and (c) fenofibrate.
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exponential factor, T = temperature in Kelvin, R = gas 
constant (8.314 J mol-1 K-1).
The aim of this paper was to develop and optimize 
an analytical HPLC method for determination of fibrates 
and possible degradation products, to evaluate the intrinsic 
stability of these drugs under stress conditions, and to 
study the kinetics of degradation of these drugs that are 
so susceptible to chemical reactions.
MATERIAL AND METHODS
Development and optimization of an analytical 
methodology for HPLC determination 
Analyses were carried out using a HPLC (Waters®) 
equipped with a UV/DAD detector, autoinjector, and oven. 
The separation methodology was based on reverse phase 
chromatography, using an octadecyl silane column (RP-
18) with a length of 30 cm to facilitate the separation of 
possible degradation products, and an UV/DAD detector 
to facilitate the identity of the degradation products, and 
reveal possible co-elutions.
Performance Parameters
The performance parameters (system suitability) 
were calculated according to formulas described by the 
Brazilian Pharmacopoeia (Brazil, 2010) for the retention 
factor (k’), peak asymmetry (As), number of theoretical 
plates (N) and resolution (Rs).
Evaluation of intrinsic stability
The initial conditions used to evaluate the intrinsic 
stability of bezafibrate, ciprofibrate and fenofibrate were:
•  Dry heat: 20 mg of each drug was dissolved in metha-
nol and subjected to dry heat in an oven at 323 K for 4 
hours. After this procedure, the samples were diluted 
in methanol to a concentration of 0.01 mg mL-1.
•  Neutral hydrolysis: 20 mg of each drug was dis-
solved in methanol. 20 mL of water was added 
and the solution was incubated in a water bath at 
323 K for 4 hours. After this procedure, the samples 
were diluted in methanol to a concentration of 
0.01 mg mL-1.
•  Alkaline hydrolysis: 20 mg of each drug was dis-
solved in methanol. 20 mL of 0.1 M NaOH was 
added and the solution was incubated in a water 
bath at 323 K for 4 hours. After this procedure, the 
samples were diluted in methanol to a concentration 
of 0.01 mg mL-1.
•  Acid hydrolysis: 20 mg of each drug was dissolved 
in methanol. 20 mL of 0.1 M HCl was added and the 
solution was incubated in a water bath at 323 K for 4 
hours. After this procedure, the samples were diluted 
in methanol to a concentration of 0.01 mg mL-1.
•  Oxidation: 20 mg of each drug was dissolved in 
methanol. 20 mL of 3% hydrogen peroxide (v/v) 
was added and the solution was incubated in a water 
bath at 323 K for 4 hours. After this procedure, the 
samples were diluted in methanol to a concentration 
of 0.01 mg mL-1.
•  Exposure to ultraviolet light: 20 mg of each drug was 
dissolved in methanol and placed in an UV radiation 
chamber under a 254 nm lamp for 4 hours. After this 
procedure, the samples were diluted in methanol to 
a concentration of 0.01 mg mL-1.
•  Solution with metal ions (FeSO4): 20 mg of each 
drug was dissolved in methanol. 20 mL of a 0.05 M 
FeSO4 solution was added and the resulting solution 
was incubated in the water bath at 323 K for 4 hours. 
After this procedure, the samples were diluted in 
methanol to a drug concentration of 0.01 mg mL-1.
After being exposed to the stress conditions and 
being diluted as described above, the samples were 
analyzed by HPLC.
Degradation kinetics studies
After the degradation studies, drugs were subjected 
to acid or base hydrolysis at 323, 333, 343 or 353 K, 
conditions under which the drugs underwent further 
degradation. Samples were collected after 4, 5, 6 and 
7 hours. The order of the degradation reactions was 
established according to the models of zero, first and 
second order kinetics.
Once each result was set to the best fit model (zero, 
first or second order), it was possible to calculate the 
degradation rate (k) for each temperature with the aid of 
the linear correlation coefficient (r).
Once the degradation rates (k) were calculated at 
each temperature, it became possible to determine, with 
the help of the Arrhenius equation, k at 298 K and thus 
indicate how long the drug takes to degrade 10% (t90). This 
is one way to determine the expiration date of a drug or 
medicament, also called t90, or shelf-life.
RESULTS AND DISCUSSION
Chromatographic conditions were optimized 
for analysis of the drugs bezafibrate, ciprofibrate and 
fenofibrate using a mobile phase consisting of methanol 
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and 0.01% phosphoric acid (80:20% v/v); octadecyl 
silane column (250 x 4.6 mm; 5 µm); wavelengths for 
bezafibrate (254 nm), ciprofibrate (236 nm), fenofibrate 
(290 nm); flow rate of 1.0 ml min-1; temperature 303 K; 
injection volume of 20 µL, and 20 minutes analysis of 
analysis.
After the HPLC analysis method was optimized, 
the performance parameters were determined for each 
compound: bezafibrate (k’ = 0.67; As = 1.41, N = 4299 
plates/column), ciprofibrate (k’ = 1.09; As = 1.35, N = 
6052 plates/column; Rs = 3.95) and fenofibrate (k’ = 3.51; 
As = 1.07, N = 13.258 plates/column; Rs = 17.77). These 
performance parameters were shown to be satisfactory 
according to the limits set for each parameter, which were 
k’ (retention factor) > 0.5, N (theoretical plates) > 2.000, 
T (tailing factor) ≤ 2, and Rs (resolution) > 2 (Ribani et 
al., 2004).
Under these conditions, the retention times differed 
for each of the compounds and were 4.31 min for 
bezafibrate, 5.4 min for ciprofibrate and 11.6 min for 
fenofibrate. The three drugs were shown to be very 
unstable and degraded in all the conditions used in the 
intrinsic stability studies. The most significant reduction 
in peak area after submission to stress conditions was due 
to acid and basic hydrolysis. In light of these results for 
intrinsic stability, the degradation kinetics were evaluated 
under the acid and basic hydrolysis conditions, initially at 
temperatures of 323 K, 333 K, 343 K and 353 K.
For bezafibrate and ciprofibrate, kinetic studies 
of drug degradation during acid and basic hydrolysis 
showed no proportional relationship between time 
and temperature, and the degradation studies were not 
reproducible. These results demonstrate the difficulty 
in deciphering the intermediate products of degradation 
kinetics, and such degradation was impossible to be fit 
to kinetic models. Previous studies of degradation under 
thermal analysis by TG (thermogravimetry) also were not 
reproducible for the experimentally determined dynamic 
TG or the isothermal TG. This lack of reproducibility 
of results when submitting bezafibrate and ciprofibrate 
to stress conditions indicates a complexity in both 
degradation processes.
There are no reports in the literature of possible 
mechanisms of  degradat ion to bezafibrate  and 
ciprofibrate. According to the molecular structures of 
each drug, it is possible to understand the complexity of 
these degradations. For bezafibrate, possible reactions 
under stress conditions could happen, such as: the 
ether group can suffer breaks in the chain when under 
acid hydrolysis; the aromatic halide group can undergo 
hydroxylation forming a phenol; and amide group can 
undergo hydrolysis, which is favored at basic or acid 
medium, resulting in alcohol and carboxylic acid. For 
ciprofibrate, under stress conditions, the ether group 
may rupture in the chain when under acid hydrolysis; the 
halide group can be converted into the alkene under basic 
hydrolysis, where it has a heated alcoholic solution and 
an inorganic base; and halide group, which is cyclic, may 
undergo elimination under basic hydrolysis obtaining an 
alicyclic hydrocarbon.
For fenofibrate, the kinetic degradation studies 
showed a significant decrease in peak area after acid and 
basic hydrolysis. Similar to the results for bezafibrate 
and ciprofibrate, under acid hydrolysis conditions 
no reproducible results were observed, and so it was 
not possible to make mathematical adjustments. This 
difficulty of adjusting the kinetic data in acid hydrolysis 
could be related to possible reactions that can happen, 
such as: the ketone group can react reversibly with the 
methanol used when under acid hydrolysis, forming 
“acetals”; the ether group can suffer breaks in the chain 
when under acid hydrolysis; the ester group can undergo 
hydrolysis, which may be favored in acid medium, 
resulting in an alcohol and a carboxylic acid; and even 
the aromatic halide group can undergo hydroxylation 
forming a phenol.
For fenofibrate, after basic hydrolysis, the results 
fit the model well and were reproducible. Figure 2 shows 
the chromatograms of fenofibrate kinetic studies after 
basic hydrolysis at different temperatures and exposure 
times. The possible mechanism of fenofibrate degradation 
reaction seems to be related to the characteristic reaction 
grouping ester hydrolysis. This mechanism has been 
described by Kumbhar et al. (2013) and Salama et al. 
(2011), and in view of the mathematical adjustment 
degradation models, this mechanism seems to be the only 
form of drug degradation in this stress condition.
The values related to the fit of the fenofibrate 
kinetic degradation data to the zero, first and second order 
mathematical models at 323, 333, 343 and 353 K are 
described in Table I.
Analysis of the calculated linear regression 
coefficient (r), suggested that the degradation kinetics of 
fenofibrate versus temperature are best described as a first 
order reaction, so the reaction rate depends on a single 
factor, which can be a reactant or product involved in the 
reaction (Brown et al., 2005).
After the reaction order was determined, the 
degradation rate constants were calculated for each 
temperature: k 323K = 0.148797926, k 333K = 0.181610946, 
k 343K = 0.381299703, and k 353K = 0.591997704. However, 
it was also possible to calculate k 298K, which was 
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0.031406672. Thus, t90 was 3.34 hours. This means that 
after 3.34 hours in 0.1 M NaOH, or equivalent pH, the 
drug has degraded 10%.
Figure 3 shows the plot of Arrhenius equation 
log k x 1/T function. The slope of the line is defined by 
the equation Ea (2,303 × R)
-1, before it was possible to 
calculate the activation energy, so being Ea = 455.14 J mol-1 
for the reaction of fenofibrate degradation. 
For ciprofibrate, after evaluations of possible 
degradation products (DP) formed in the reaction, 
it was possible to study the kinetics of formation of 
these degradation products formed upon exposure to 
acid hydrolysis. Thus, the kinetic studies indicated a 
mathematical fit on the kinetics of formation of a DP 
(retention time = 6.61 min) of ciprofibrate in acid medium. 
Figure 4 shows chromatograms of ciprofibrate kinetic 
study in acid hydrolysis, noting that the kinetic studies 
were performed for the degradation product formed in 
6.61 min.
The values  repor ted  in  Table  I I  show the 
mathematical fits of the zero, first and second order models 
of a ciprofibrate degradation product at temperatures of 
323 K, 333 K, 343 K and 353 K. It can be observed from 
Table II that the best fit is the first order model, where 
the correlation coefficient was the closest to 1.000, thus 
defining the order of the reaction. The rate constants were 
calculated for each temperature: k 323 K = 68644.24, k 333 K 
= 104592.10, k 343 K = 137831.45 and k 353 K = 235535.56. 
Using the Arrhenius Equation graphical method (Figure 
6) it was possible to calculate k at 298 K, which was 
20812.63. The Arrhenius equation was used to determine 
the activation energy (Ea), Ea = 370.88 J mol
-1 to form of 
the degradation product of ciprofibrate.
CONCLUSIONS
The HPLC analysis method was optimized by 
introducing appropriate performance parameters for the 
three drugs.
The three drugs have proved extremely unstable in 
liquid media, undergoing reactions in each of the tested 
stress conditions. The most significant instability was 
related to acid and basic hydrolysis.
It was not possible to study the kinetics of bezafibrate 
and ciprofibrate degradation since the degradation of 
these drugs exhibits no proportionality between time 
FIGURE 2 - Chromatograms of the fenofibrate solution before (standard) and after 4, 5, 6 or 7 hours of basic hydrolysis at 323, 
333, 343 or 353 K.
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and temperature, and therefore could not be fit to kinetic 
models. However, it was possible to study the kinetics of 
the formation of a ciprofibrate degradation product with 
an Ea of 370.88 J mol-1.
In the evaluation of fenofibrate basic hydrolysis 
degradation kinetics, the reaction was shown to be first 
order with a t90 value of 3.34 hours. These analyses 
demonstrate the instability of the drug when exposed to 
0.1 M NaOH or an equivalent pH.
The absence of liquid dosage forms for fibrates 
on the market can be understood given the instability of 
the drugs as we have shown by degradation and kinetic 
studies.
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TABLE I - Kinetic data for the degradation of fenofibrate under basic hydrolysis at 323, 333, 343 and 353 K
Temperature (K) Parameter
Order
Zero First Second
323
a 
b 
r
-10.12976 
96.91408 
-0.97008
-0.06461 
1.98355 
-0.97819
0.00231 
0.010441 
0.98616
333
a 
b 
r
-10.45412 
94.03265 
-0.95643
-0.07886 
1.96967 
-0.97922
0.00357 
0.01052 
0.99558
343
a 
b 
r
-13.86424 
90.43891 
-0.94528
-0.16557 
1.96678 
-0.99370
0.01754 
0.00065 
0.95795
353
a 
b 
r
-14.74440 
88.03679 
-0.92663
-0.25706 
1.95949 
-0.99007
0.08259 
-0.08093 
0.80273
The data were best fit to a line of type Y = a X + b, where a is the slope, b is the y-intercept and r is the linear regression coefficient.
FIGURE 3 - Arrhenius equation graph extrapolated to 298 K for the drug fenofibrate. The arrow identifies k298 K.
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FIGURE 4 - Chromatograms of the ciprofibrate solution before (standard) and after 4, 5, 6 or 7 hours under acid hydrolysis at 
temperatures of 323, 333, 343 and 353 K.
TABLE II - Kinetic data for ciprofibrate degradation under acid hydrolysis at 323, 333, 343 or 353 K 
Temperature (K) Parameter
Order
Zero First Second
323 a 
b 
r
29806.44521 
-3554.958904 
0.97959
0.10016 
4.63585 
0.92342
-1.63613E-06 
1.57726E-05 
-0.91602
333 a 
b 
r
45415.58904 
9593.80822 
0.99340
0.05794 
5.09438 
0.99350
-5.17395E-07 
6.75259E-06 
-0.99265
343 a 
b 
r
59848.65385 
41.63462 
1.00000
0.07978 
5.06706 
0.99744
-5.78635E-07 
6.38697E-06 
-0.98889
353 a 
b 
r
102273.363 
30729.60274 
0.98866
0.04994 
5.50056 
0.99517
-1.95E-07 
2.76459E-06 
-0.99032
The data were best fit to a line of type Y = a X + b, where a is the slope, b is the y-intercept and r is the linear regression coefficient.
M. A. Oliveira, G. D. Silva, M. S. T. Campos552
FIGURE 5 - Graph of the Arrhenius equation extrapolated to 298 K for a ciprofibrate degradation product. The arrow identifies k298 K.
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